BioSpace News Archive

In connection with the publication of the Interim Report for Q3 2020, an updated guiding was shared for the full year 2020.

BiomX Inc. (NYSE American: PHGE), a clinical stage company developing natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the first subject has been dosed in a Phase 1a study of BX002, a phage therapy candidate for the treatment of inflammatory bowel disease (IBD).

BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced noninvasive treatment of brain disorders, today announced that it will report its third quarter 2020 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, November 18, 2020.

Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Tuesday, November 10, 2020 to report its third quarter 2020 financial results and discuss recent business highlights.

Helius Medical Technologies, Inc. (Nasdaq: HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that the Company has expanded its authorized clinic network to a total of 27 Authorized PoNS Treatment™ Clinic locations spanning across Canada

Surgery Partners, Inc. (NASDAQ:SGRY) (“Surgery Partners” or the “Company”), a leading short-stay surgical facility owner and operator, today announced results for the third quarter ended September 30, 2020.

The state of digestive health plays an important role in determining the overall health of a human body.

In cell separation technology, heterogeneous cell mixture is separated from cells, pm the basis of extracellular and properties of the cells.

Venipuncture is a technique used in allopathic medicine to gain entry into the human body in a minimally invasive manner.

Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX:TBP)(OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, today provided an update on the potential market of its new drug, ARDS-003